Skip to content
New: 30 more Indian companies explained, from Ather and Pine Labs to IDBI Bank

Healthcare · NSE: APOLLOHOSP · BSE: 508869

Apollo Hospitals: how the business works

Apollo Hospitals treats patients in 48 hospitals of its own and supplies 7,662 Apollo pharmacies; FY26 revenue was ₹24,774 crore.

Follow Apollo Hospitals

Email me when Apollo Hospitals's page is updated after results.

We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.

Apollo Hospitals Enterprise Limited · Chennai, Tamil Nadu · Founded 1983

Updated for Q2 FY27 · checked

Revenue, FY26 (without Cradle and Fertility)
₹24,774 cr
Profit to shareholders, FY26
₹1,942 cr
Own hospitals and operating beds, 30 Sep 2026
48 · 8,522 beds
Pharmacy stores supplied, 30 Sep 2026
7,662
Promoter holding, Sep 2026 (2.91% of it pledged)
28.02%

For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

The short version

Apollo Hospitals in 5 points

  1. 1 · What it sells

    Apollo Hospitals runs 48 hospitals of its own with 8,522 operating beds, supplies 7,662 Apollo pharmacy stores and runs clinics and diagnostic centres, and its Q2 FY27 revenue was ₹7,615 crore.

    More: what it sells

  2. 2 · Who pays it

    In FY26, hospital patients and their insurers paid for 50.1% of Apollo's segment revenue, pharmacy stores and online medicine buyers 42.5%, and clinic and diagnostics patients 7.3%.

    More: who pays it

  3. 3 · What it keeps from ₹100

    Of every ₹100 that came in during FY26, as first reported, Apollo spent ₹51.4 on medicines and supplies and ₹11.8 on employees, and kept ₹7.6 as profit for shareholders.

    More: what it keeps from ₹100

  4. 4 · Where the operating profit comes from

    Hospitals earned ₹2,430 crore of Apollo's ₹2,893 crore FY26 segment profit before interest and tax, or 84.0%, against ₹399 crore from pharmacy and Apollo 24/7 and ₹72 crore from clinics and diagnostics.

    More: where the operating profit comes from

  5. 5 · The one thing to watch

    Apollo plans to move pharmacy and Apollo 24/7, 42.5% of FY26 segment revenue, into the separately listed Apollo Healthtech, and management said on 5 Nov 2026 it expects the demerger in Q4 FY27.

    More: the one thing to watch

Sources: From Apollo Hospitals' FY26 results, its Q2 FY27 results and investor deck, and its 5 Nov 2026 earnings call · checked

01Where the money goes · FY26

Where does ₹100 of Apollo Hospitals' money go?

Of every ₹100 that came in (revenue plus other income), this is where it went.

Apollo Hospitals · FY26

Receipt for every ₹100

Where ₹100 of Apollo Hospitals' money went in FY26
Medicines, consumables and goods for resale₹51.4
Employees₹11.8
Other running costs₹21.2
Depreciation and interest₹5.2
Income tax₹2.6
One-off charge and minority share, less part-owned companies' profit₹0.1
Kept as profit for shareholders₹7.6
Total₹100

Each line = amount ÷ total money in × 100. Lines may not add to exactly ₹100 because of rounding.

How this is worked out

Of every ₹100 that came in during FY26 (₹25,229 crore of revenue as first reported, including Cradle and Fertility, plus ₹192 crore of other income), Apollo kept ₹7.6 as profit for its shareholders. Each line = amount ÷ ₹25,420 crore × 100 (Cityfort calculation from the FY26 results).

Save this receipt as an image

Embed this receipt or the key numbers

Paste this code into a blog or website to show the card you choose, with a link back to this page.

Each week: the next company due to report results, explained in 5 points.

We'll email you once a week with what changed on Cityfort. Facts only, no tips. Unsubscribe any time.

We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.

02The business in one line

What does Apollo Hospitals do?

Patients, insurers and pharmacy stores pay Apollo for treatment and medicines; just over half of every ₹100 goes on medicines and supplies, and ₹7.6 is left as profit.

  • Hospitals were 50.1% of FY26 segment revenue but earned 84.0% of segment profit (₹2,430 crore of ₹2,893 crore; Cityfort calculation from the FY26 results).
  • Pharmacy distribution and Apollo 24/7 were 42.5% of segment revenue. A scheme awaiting tribunal sanction moves them into a separate listed company, Apollo Healthtech.

03Who pays it

Who pays Apollo Hospitals?

  • Hospital patients, their insurers and government schemes

    50.1%

    of revenue

    Pay for treatment in Apollo's hospitals. Management said insurance and self-paying patients gave 82% of inpatient revenue in Q2 FY27; the company's other payer groups are public-sector and government payers, and international patients.

  • Pharmacy stores and online medicine buyers

    42.5%

    of revenue

    Apollo HealthCo's revenue from supplying Apollo pharmacy stores and from online sales through Apollo 24/7. Offline pharmacy distribution was ₹2,885 crore of its ₹3,286 crore revenue in Q2 FY27.

  • Clinic, diagnostics and day-surgery patients

    7.3%

    of revenue

    AHLL's revenue. In Q2 FY27, diagnostics brought in ₹227 crore, primary care ₹139 crore and specialty care ₹84 crore.

  • Hospital patients, their insurers and government schemes50.1%
  • Pharmacy stores and online medicine buyers42.5%
  • Clinic, diagnostics and day-surgery patients7.3%

How spread out the customers are

Shares are each segment's FY26 revenue before sales between segments, divided by their total of ₹25,429 crore (Cityfort calculation from the FY26 results). The filings collected give no revenue by single customer. CRISIL says Apollo HealthCo is the exclusive supplier of the Apollo pharmacy stores run by Apollo Pharmacies Ltd.

04How it makes money

How does Apollo Hospitals make money?

Hospitals earn more as beds fill and cases get more complex; new hospitals lose money while they fill.

Apollo's established hospitals had an EBITDA margin (profit before interest, tax and wear-and-tear, per ₹100 of revenue) of 25.8% in Q2 FY27. New hospitals lost ₹35 crore at that level. Average revenue per inpatient rose from ₹142,958 in FY22 to ₹178,434 in FY26.

Average revenue per inpatient (₹)

₹142,958₹178,434

FY22 to FY26

  1. Patients come for complex care: heart, cancer, brain, gut, bone and transplant cases were 61% of inpatient revenue in Q2 FY27.
  2. Insurers and patients pay for each stay: average revenue per inpatient was ₹186,880 in Q2 FY27.
  3. Occupancy rose to 73% in Q2 FY27, from 69% a year earlier.
  4. Established hospitals kept an EBITDA margin of 25.8% in Q2 FY27.
  5. That money pays for new capacity: 1,395 census beds across FY26 and FY27.
  6. New hospitals lost ₹35 crore of EBITDA in Q2 FY27 while they fill.

↺ Step 6 feeds back into step 1.

05Business segments · FY26

Which businesses make up Apollo Hospitals?

  • Hospitals

    50.1%

    Healthcare services: treatment in Apollo's own hospitals. Its ₹2,430 crore segment profit was 84.0% of the FY26 segment total (Cityfort calculation).

    Revenue ₹12,750 cr · Operating profit ₹2,430 cr

  • Pharmacy and Apollo 24/7

    42.5%

    Apollo HealthCo: medicines supplied to Apollo pharmacy stores and sold online, plus the Apollo 24/7 app. The pending scheme moves it out of Apollo.

    Revenue ₹10,808 cr · Operating profit ₹399 cr

  • Clinics and diagnostics

    7.3%

    AHLL: clinics, diagnostics, day surgery, dialysis and dental. FY26 still includes Cradle and Fertility, sold on 12 Oct 2026.

    Revenue ₹1,865 cr · Operating profit ₹72 cr

How the mix changed

  • Hospitals
  • Pharmacy and Apollo 24/7
  • Clinics and diagnostics

Revenue by segment, FY23 to FY26.

₹ crore

See the numbers
How the mix changed (₹ crore)
YearHospitalsPharmacy and Apollo 24/7Clinics and diagnostics
FY23₹8,743₹6,705₹1,231
FY24₹9,939₹7,827₹1,364
FY25₹11,220₹9,093₹1,554
FY26₹12,750₹10,808₹1,865

06The numbers · Consolidated · ₹ crore

How has Apollo Hospitals done?

Revenue

₹24,774 crFY26

Revenue rose every year from ₹14,663 crore in FY22 to ₹24,774 crore in FY26, and Q2 FY27's ₹7,615 crore was 23% above Q2 FY26 on the company's basis; FY26, Q2 FY26 and Q1 FY27 are re-presented without Cradle and Fertility, while the other periods still include them.

₹ crore

See the numbers
Revenue (₹ crore)
PeriodRevenue (₹ cr)
FY22₹14,663
FY23₹16,613
FY24₹19,059
FY25₹21,794
FY26₹24,774
Q1 FY25₹5,086
Q2 FY25₹5,589
Q3 FY25₹5,527
Q4 FY25₹5,592
Q1 FY26₹5,842
Q2 FY26₹6,189
Q3 FY26₹6,477
Q4 FY26₹6,606
Q1 FY27₹6,932
Q2 FY27₹7,615

Net profit

₹1,942 crFY26

Profit for shareholders rose from ₹819 crore in FY23 to ₹1,942 crore in FY26 and was ₹630 crore in Q2 FY27, up 32% from a year earlier; FY22's ₹1,056 crore included a ₹294 crore one-off gain.

₹ crore

See the numbers
Net profit (₹ crore)
PeriodNet profit (₹ cr)EPS (₹)
FY22₹1,056₹73.42
FY23₹819₹56.97
FY24₹899₹62.50
FY25₹1,446₹100.56
FY26₹1,942₹135.04
Q1 FY25₹305₹21.23
Q2 FY25₹379₹26.34
Q3 FY25₹372₹25.89
Q4 FY25₹390₹27.10
Q1 FY26₹433₹30.10
Q2 FY26₹477₹33.19
Q3 FY26₹502₹34.94
Q4 FY26₹529₹36.82
Q1 FY27₹581₹40.39
Q2 FY27₹630₹43.82

Net profit for every ₹100 of revenue

₹7.7FY26

Profit per ₹100 of revenue fell from ₹7.2 in FY22 to ₹4.7 in FY24 and rose to ₹7.7 in FY26 (on ₹25,229 crore of revenue as first reported, since FY26 profit still includes Cradle and Fertility); FY22 EBITDA of ₹2,479 crore includes a ₹294 crore one-off gain (₹2,185 crore before it, Cityfort calculation), and FY26 and Q1 FY27 EBITDA are blank because re-presented figures are not disclosed (as first reported: ₹3,750 crore, 14.9%, and ₹1,092 crore).

Net margin: ₹ of net profit per ₹100 of revenue

See the numbers
Net profit for every ₹100 of revenue (Net margin: ₹ of net profit per ₹100 of revenue)
YearNet marginEBITDA margin
FY227.2%16.9%
FY234.9%12.3%
FY244.7%12.6%
FY256.6%13.9%
FY267.7%–

Free cash flow

₹894 crFY26

Free cash flow was ₹894 crore in FY26 after ₹1,962 crore of capital spending, and fell to ₹293 crore in H1 FY27 from ₹619 crore in H1 FY26 as capital spending rose to ₹1,200 crore.

₹ crore · cash from operations minus spending on plants and equipment

See the numbers
Free cash flow (₹ crore · cash from operations minus spending on plants and equipment)
YearCash from operationsCapital spendingFree cash flow
FY22₹1,616₹657₹959
FY23₹1,377₹1,129₹249
FY24₹1,920₹1,137₹784
FY25₹2,136₹1,713₹424
FY26₹2,856₹1,962₹894
See all yearly numbers
Apollo Hospitals annual financials, FY22–FY26, ₹ crore
YearRevenueEBITDANet profitEPS (₹)Operating cashCapexFree cash
FY22₹14,663₹2,479₹1,056₹73.42₹1,616₹657₹959
FY23₹16,613₹2,050₹819₹56.97₹1,377₹1,129₹249
FY24₹19,059₹2,393₹899₹62.50₹1,920₹1,137₹784
FY25₹21,794₹3,022₹1,446₹100.56₹2,136₹1,713₹424
FY26 (restated)₹24,774–₹1,942₹135.04₹2,856₹1,962₹894

EBITDA = profit before interest, tax and wear-and-tear of assets. Financial year runs April to March (March year end). Net profit is the share belonging to the company's owners.

07Who runs it

Who runs Apollo Hospitals, and did they deliver?

  • Dr Prathap C. Reddy

    Founder and Executive Chairman

    Founded Apollo Hospitals in 1983, according to the annual report.

  • Dr Preetha Reddy

    Executive Vice Chairperson

  • Suneeta Reddy

    Managing Director

    Signs the results and opened the Q2 FY27 earnings call.

  • Dr Sangita Reddy

    Joint Managing Director

  • A. Krishnan (Krishnan Akhileswaran)

    Group Chief Financial Officer

  • Dr Madhu Sasidhar

    President and CEO, Hospitals Division

    Leaves on 14 Nov 2026 at the end of his tenure; his functions move to a programme management office under the MD.

What they said, and what happened

4 too early to tell · 1 partly delivered

  1. Said on 21 May 2026

    Group CFO A. Krishnan said Apollo Healthtech should "hopefully, by Q4 FY27" be demerged and listed, after a tribunal process he put at 3 to 4 months.

    What happened

    Shareholders approved the scheme on 24 Jun 2026 and Apollo filed for tribunal sanction. MD Suneeta Reddy repeated the Q4 FY27 expectation on 5 Nov 2026.

    Too early to tell
  2. Said on 21 May 2026

    Group CFO A. Krishnan said the established hospitals' margin should improve "by at least 100 basis points" (1 percentage point) in FY27, with about ₹150 crore of EBITDA losses from new hospitals.

    What happened

    In Q2 FY27 the established hospitals' EBITDA margin was 25.8%, up 0.61 percentage points from a year earlier. New-hospital losses were ₹37.5 crore in Q1 FY27 and ₹34.8 crore in Q2 FY27 in the company's decks.

    Too early to tell
  3. Said on 21 May 2026

    Apollo HealthCo CFO Sanjiv Gupta said the digital business should break even before ESOP costs in Q1 FY27, and including ESOP costs by Q3 FY27.

    What happened

    Q1 FY27 showed a digital cash loss of ₹9.7 crore before ESOP costs. Q2 FY27 showed a cash profit of ₹1.3 crore before ESOP costs. The Q3 FY27 milestone is still ahead.

    Partly delivered
  4. Said on 21 May 2026

    Group CFO A. Krishnan said Apollo Healthtech would reach a ₹25,000 crore annualised revenue run rate by Q4 FY27, with a 6.5% to 7% EBITDA margin.

    What happened

    The Q2 FY27 deck (4 Nov 2026) says the company expects ₹25,000 crore of revenue and ₹1,500 crore of EBITDA annualised for Q4 FY27; ₹1,500 crore is 6% of ₹25,000 crore (Cityfort calculation).

    Too early to tell
  5. Said on 5 Nov 2026

    Group CFO A. Krishnan said the Gurugram hospital would launch in the coming quarter (Q3 FY27).

    What happened

    Not yet reported.

    Too early to tell

08What could go wrong

What could go wrong for Apollo Hospitals?

  • Execution

    Demerger of pharmacy and Apollo 24/7

    A scheme would move pharmacy distribution and Apollo 24/7, 42.5% of FY26 segment revenue, into Apollo Healthtech. CRISIL says Apollo would keep an economic interest of about 17.5%. Shareholders approved it on 24 Jun 2026; tribunal sanction was pending at the Q2 FY27 results. No restated history without the business has been published.

    Watch NCLT Chennai's sanction and the first results after the demerger; management said on 5 Nov 2026 it expects completion in Q4 FY27.

  • Regulation

    Price controls on treatment and devices

    CRISIL notes that government price caps on cardiac stents and knee implants hurt Apollo's revenue and profit in FY17 and FY18. States also capped Covid treatment charges in 2020.

    Watch Government notices capping prices of procedures, devices or medicines.

  • Execution

    New hospitals take time to fill

    Apollo is opening 1,395 census beds across FY26 and FY27; 520 were open by Sep 2026. The company puts its full expansion plan at about ₹11,150 crore, with about ₹7,100 crore still to spend. New hospitals lost ₹35 crore of EBITDA in Q2 FY27.

    Watch New-hospital losses each quarter against the ₹150 crore FY27 figure management gave, and Gurugram's opening.

  • Governance

    Promoter shares pledged

    On 30 Sep 2026, 2.91% of the promoter group's shares were pledged as loan collateral, up from 2.49% in Jun 2026 and down from 16.09% in Dec 2023. In Aug 2025 the promoter group sold 1.3% of Apollo to reduce promoter-group debt.

    Watch The pledge level in each quarterly shareholding filing.

  • Legal

    Karnataka land order

    Karnataka's Revenue Department cancelled a land grant to subsidiary Imperial Hospitals & Research Centre on 13 Feb 2026, alleging the land was alienated through a share purchase by its holding company. The High Court granted an interim stay against the order on 10 Apr 2026. Apollo says external legal opinions give it adequate grounds to show compliance. No amount is stated.

    Watch The High Court of Karnataka's decision.

  • Execution

    Apollo 24/7 still near break-even

    CRISIL says Apollo spent about ₹640 crore a year on Apollo 24/7 in FY23 and FY24, which pushed the pharmacy business into operating losses. The digital business made a ₹1.3 crore cash profit before ESOP costs in Q2 FY27, but an ₹8.3 crore cash loss in H1 FY27.

    Watch Q3 FY27 digital results including ESOP costs, the milestone management gave in May 2026.

  • Governance

    Leadership and auditor changes

    Dr Madhu Sasidhar, President and CEO of the hospitals division, leaves on 14 Nov 2026. Dinesh Madhavan, President of Group Oncology and International, resigned in May 2026. Deloitte's final term as auditor ends at the 2027 annual meeting.

    Watch Who leads the hospitals division and who becomes the next auditor.

09Supporters and critics

What do supporters and critics point to?

Facts each side points to. We don't say which side is right.

What supporters point to

  • Revenue rose every year from FY22 to FY26, and Q2 FY27 revenue was 23% higher than a year earlier on the company's re-presented basis.
  • Established hospitals earned a 25.8% EBITDA margin in Q2 FY27, and occupancy reached 73%.
  • ICRA assigned [ICRA]AAA (Stable) in May 2026; CRISIL rates Apollo AA+ with a Positive outlook (Jan 2026).
  • Apollo 24/7 made its first cash profit before ESOP costs in Q2 FY27, ₹1.3 crore, against a ₹39 crore loss a year earlier.
  • The promoter pledge fell from 16.09% of promoter shares in Dec 2023 to 2.91% in Sep 2026.

What critics point to

  • Free cash flow fell to ₹293 crore in H1 FY27 from ₹619 crore in H1 FY26, as capital spending rose to ₹1,200 crore.
  • New hospitals lost ₹35 crore of EBITDA in Q2 FY27, and about ₹7,100 crore of the expansion plan is still to be spent.
  • Reported borrowings of ₹5,595 crore on 30 Sep 2026 were more than twice cash of ₹2,381 crore, and lease liabilities (₹2,834 crore, Mar 2026) come on top.
  • The demerger would move 42.5% of FY26 segment revenue out of Apollo, and no restated history without it has been published.
  • In Nov 2026 the company's Q4 FY27 aim for Apollo Healthtech was ₹1,500 crore EBITDA on ₹25,000 crore annualised revenue, 6%, below the 6.5–7% margin given in May 2026.

10What to watch next

What should you watch next at Apollo Hospitals?

Next event

Q3 FY27 results

Date not announced yet.

  • Tribunal sanction of the demerger

    NCLT Chennai has to sanction the Apollo Healthtech scheme. Management said on 5 Nov 2026 it expects completion in Q4 FY27.

  • Gurugram and new-hospital losses

    Group CFO A. Krishnan said on 5 Nov 2026 that Gurugram would launch in the coming quarter. New hospitals lost ₹35 crore of EBITDA in Q2 FY27.

  • Apollo 24/7 after ESOP costs

    In May 2026 Apollo HealthCo's CFO said digital should break even including ESOP costs by Q3 FY27. Q2 FY27 showed a ₹1.3 crore cash profit before them.

  • Hospital leadership

    Dr Madhu Sasidhar leaves on 14 Nov 2026; his functions move to an office under the MD.

11Key facts

Key facts about Apollo Hospitals

What does Apollo Hospitals do?
Apollo Hospitals Enterprise Ltd (Apollo Hospitals) runs private hospitals in India: 48 of its own, with 8,522 operating beds, on 30 Sep 2026. Through its subsidiary Apollo HealthCo it also supplies 7,662 Apollo pharmacy stores and runs the Apollo 24/7 health app.
How does Apollo Hospitals make money?
Apollo Hospitals charges for treatment in its hospitals and earns a margin on the medicines it supplies. In FY26 hospitals were 50.1% of Apollo Hospitals' segment revenue but earned ₹2,430 crore of its ₹2,893 crore segment profit before interest and tax.
Who pays Apollo Hospitals?
Insurance companies and patients paying for themselves gave 82% of Apollo Hospitals' inpatient revenue in Q2 FY27, the company said on its 5 Nov 2026 earnings call. Pharmacy stores and online medicine buyers paid for 42.5% of Apollo Hospitals' FY26 segment revenue.
How big is Apollo Hospitals?
Apollo Hospitals' FY26 revenue was ₹24,774 crore, re-presented without the Cradle and Fertility units it sold in Oct 2026, and its FY26 profit for shareholders was ₹1,942 crore. Apollo Hospitals' Q2 FY27 revenue was ₹7,615 crore.
Who owns Apollo Hospitals?
On 30 Sep 2026 Apollo Hospitals' promoter group held 28.02% of the shares, foreign investors 43.18%, Indian institutions 22.07%, individuals and others 6.49% and state governments 0.23%. 2.91% of the promoter group's Apollo Hospitals shares were pledged as loan collateral.
What is the Apollo Healthtech scheme?
Apollo Hospitals' board approved a scheme on 30 Jun 2025 to move the pharmacy distribution and Apollo 24/7 business into Apollo Healthtech Ltd, which would list on the stock exchanges. Apollo Hospitals shareholders would get 195.2 Apollo Healthtech shares for every 100 Apollo Hospitals shares. The scheme had not taken effect on 30 Sep 2026.
What dividend does Apollo Hospitals pay?
Apollo Hospitals declared ₹20 a share for FY26 (₹10 interim and ₹10 final), up from ₹19 a share for FY25 and ₹16 for FY24.
How much does Apollo Hospitals borrow?
On 30 Sep 2026 Apollo Hospitals reported borrowings of ₹5,595 crore and cash and short-term investments of ₹2,381 crore. On 31 Mar 2026, ₹2,457 crore of Apollo Hospitals' reported borrowings were preference shares that must convert into shares of its subsidiary Apollo HealthCo.

Terms on this page

Each explains the term in plain English, with the same number from other companies on Cityfort.

Go deeper

More detail from the same filings. Open any section.

12What it sells

12What it sells

What does Apollo Hospitals sell?

Apollo runs private hospitals where patients get surgery, cancer care, transplants and other complex treatment. Its subsidiary Apollo HealthCo supplies medicines to Apollo pharmacy stores and runs the Apollo 24/7 app. A third arm runs clinics and diagnostic centres.
  • Hospitals

    48 hospitals of its own with 8,522 operating beds on 30 Sep 2026, plus 6 it manages for other owners. Heart, cancer, brain, gut, bone and transplant care made up 61% of inpatient revenue in Q2 FY27.

  • Pharmacy distribution (Apollo HealthCo)

    Supplies medicines to 7,662 Apollo pharmacy stores (30 Sep 2026). Apollo's own private-label and generic products were about 15.3% of omni-channel pharmacy sales in Q2 FY27.

  • Apollo 24/7 app

    An app for ordering medicines, seeing a doctor online and booking tests: over 51 million registered users, about 57,400 medicine orders and 16,400 consultations a day in Q2 FY27.

  • Clinics and diagnostics (AHLL)

    Apollo Health and Lifestyle runs 292 primary-care clinics, 2,922 diagnostic collection points, 23 Spectra units, 196 dialysis centres and 300 dental clinics (30 Sep 2026).

What it does

  • Does: Treats patients in its own hospitals and bills them, their insurers or government schemes.
  • Does: Supplies medicines wholesale to Apollo pharmacy stores and sells online through Apollo 24/7.
  • Does: Runs clinics, diagnostic collection centres, dialysis and day-surgery units.
  • Does: Treats patients who travel from abroad: their revenue rose 37% in Q2 FY27, management said.

What it does not do

  • Does not: Own the Apollo pharmacy stores outright: CRISIL (Jan 2026) says Apollo Pharmacies Ltd runs them; Apollo HealthCo held 25.5% of its holding company and agreed to buy the other 74.5%.
  • Does not: Own Cradle maternity hospitals or Apollo Fertility any more: it sold them to Kids Clinic India (Cloudnine) on 12 Oct 2026.
  • Does not: Count the Delhi Apollo hospital line by line: Indraprastha Medical Corporation is jointly controlled, though its patients appear in Apollo's hospital statistics.
  • Does not: Plan to keep pharmacy and Apollo 24/7: a scheme awaiting tribunal sanction moves them to a separate company.
13How the money flows

13How the money flows · FY26

How does money flow through Apollo Hospitals?

Money in

  • Revenue from operations (FY26 as first reported, including Cradle and Fertility)₹25,229 cr
  • Other income₹192 cr

The company

Apollo Hospitals

₹25,421 cr came in

Money out

  • Medicines, consumables and goods for resale₹13,076 cr
  • Employee costs₹3,000 cr
  • Other running costs₹5,383 cr
  • Depreciation and interest₹1,326 cr
  • Income tax₹658 cr
  • One-off labour-code charge and minority holders' share, less part-owned companies' profit₹35 cr
  • Net profit for Apollo shareholders₹1,942 cr
  1. In FY26 Apollo's hospitals, pharmacy supply and clinics brought in ₹25,229 crore as first reported, plus ₹192 crore of other income.
  2. Medicines, consumables and goods bought for resale took ₹13,076 crore, the biggest cost.
  3. Employees took ₹3,000 crore and other running costs ₹5,383 crore.
  4. Depreciation and interest took ₹1,326 crore, and income tax ₹658 crore.
  5. After ₹35 crore of smaller items, ₹1,942 crore was left as profit for Apollo's shareholders.
14What it needs to run

14What it needs to run

What does Apollo Hospitals need to run?

  • Hospital beds

    8,522 operating beds in 48 hospitals of its own on 30 Sep 2026, out of a capacity of 9,650 census beds (beds counted for occupancy). Occupancy was 73% in Q2 FY27.

  • Doctors, nurses and staff

    44,008 permanent employees in the group in FY26, 51.15% of them women (BRSR). Management linked the new hospitals' losses partly to hiring new doctors.

  • Money for new hospitals

    The company puts the cost of its expansion plan at about ₹11,150 crore, with about ₹7,100 crore still to spend (Q2 FY27 deck).

  • Medicines to resell

    Goods bought for resale cost ₹10,056 crore in FY26, mostly medicines for the pharmacy business.

15Where growth could come from

15Where growth could come from

Where could Apollo Hospitals' growth come from?

Group CFO A. Krishnan said on the Q4 FY26 call (21 May 2026) that hospitals should see "a mid-teen growth into FY27". On the Q2 FY27 call (5 Nov 2026), MD Suneeta Reddy said 520 of 1,395 planned census beds were commissioned, with the rest due in 12 to 18 months.
Management statement, 21 May 2026. Reported as a statement, not our forecast.
  • Established hospitals

    Working

    Revenue ₹3,765 crore, +19%, Q2 FY27

    Management said inpatient volumes rose 14% and occupancy reached 73% in Q2 FY27. Established hospitals' EBITDA margin was 25.8%, up 0.61 percentage points from a year earlier.

    Status: Working, on track against what the company said.

  • New hospitals

    Early

    520 of 1,395 census beds open, Sep 2026

    New hospitals in Pune, Kolkata, Hyderabad, Delhi and Bengaluru brought in ₹135 crore in Q2 FY27, with an EBITDA loss of ₹35 crore. Group CFO A. Krishnan said on 5 Nov 2026 that Gurugram would launch in the coming quarter.

    Status: Early, too early to judge.

  • Patients from abroad

    Working

    International patient revenue +37%, Q2 FY27

    MD Suneeta Reddy said on 5 Nov 2026 that revenue from international patients rose 37% from a year earlier. The amount was not given.

    Status: Working, on track against what the company said.

  • Pharmacy and Apollo 24/7

    Working

    Apollo HealthCo revenue ₹3,286 crore, +23%, Q2 FY27

    Stores supplied rose to 7,662. Apollo 24/7 had its first quarter of digital cash profit before employee share-option (ESOP) costs: ₹1.3 crore, against a ₹39 crore loss a year earlier.

    Status: Working, on track against what the company said.

  • Clinics and diagnostics

    Working

    AHLL revenue ₹429 crore, +20%, Q2 FY27

    Growth is on the company's basis without Cradle and Fertility. Management said AHLL's EBITDA rose 79% to ₹61 crore.

    Status: Working, on track against what the company said.

  • Apollo Healthtech listing

    Early

    Shareholders approved 24 Jun 2026; tribunal sanction pending

    Pharmacy, Apollo 24/7 and Keimed, a drug wholesaler, would combine into Apollo Healthtech and list. CRISIL says Apollo would keep an economic interest of about 17.5%. MD Suneeta Reddy said on 5 Nov 2026: "We expect the demerger to be completed in quarter four of FY27."

    Status: Early, too early to judge.

Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.

16Financial strength and debt

16Financial strength · 30 Sep 2026

How much debt does Apollo Hospitals have?

On 30 Sep 2026 Apollo's reported borrowings were ₹3,214 crore more than its cash and short-term investments; part of those borrowings are preference shares that convert into shares, not repayments.
  • Total debt₹5,595 cr
  • Cash and investments₹2,381 cr
  • Net debt (debt minus cash)₹3,214 cr
  • Net worth (shareholders' money)₹10,604 cr
Debt to equity
0.53×
₹ of debt for every ₹1 of shareholders' money
  • Reported borrowings include compulsorily convertible preference shares (CCPS) that Apollo HealthCo issued to Rasmeli, an associate of the private equity fund Advent International, for ₹2,475 crore. They must convert into Apollo HealthCo shares within 19 years and 9 months, or earlier on set events.
  • On 31 Mar 2026 the CCPS were ₹2,457 crore of reported borrowings of ₹5,659 crore. Without them, borrowings were ₹3,201 crore (Cityfort calculation: ₹5,659 crore − ₹2,457 crore, FY26 annual report).
  • Management estimated on 31 Mar 2026 that the CCPS would convert within a year, so they were moved to short-term borrowings.
  • The 30 Sep 2026 results do not give the CCPS amount. The company's own gross debt for that date, which leaves them out, was ₹3,132 crore, and its net debt ₹629 crore (Q2 FY27 deck).
  • Lease liabilities (rent owed under leases), ₹2,834 crore on 31 Mar 2026, are not part of borrowings.
  • Debt-to-equity here = reported borrowings ÷ equity of Apollo's shareholders (₹10,604 crore), a Cityfort calculation. The annual report gives 0.26 for FY26 on the company's own gross-debt basis.
  • Cash and short-term investments = cash, other bank balances and current investments.
17Who owns it

17Who owns it · Q2 FY27

Who owns Apollo Hospitals?

  • Promoters (founders or parent company)28.0%, of which pledged 0.8%
  • Foreign institutions (FII)43.2%
  • Indian institutions (DII)22.1%
  • Public and others6.7%
  • Pledged: 2.9% of promoter shares (0.8% of all shares)0.8%

Promoter shares pledged

2.9% of promoter shares

A pledge means promoters gave shares as security for a loan. If the loan isn't repaid, the lender can sell them.

How ownership changed
Apollo Hospitals shareholding by quarter, %
QuarterPromotersFIIDIIPublicPledged*
Q3 FY2429.3%46.3%18.9%5.3%16.1%
Q4 FY2429.3%45.6%19.6%5.3%16.1%
Q1 FY2529.3%43.9%21.1%5.4%16.1%
Q2 FY2529.3%45.4%20.0%5.1%14.0%
Q3 FY2529.3%45.3%20.0%5.2%13.5%
Q4 FY2529.3%42.7%22.3%5.4%13.5%
Q1 FY2629.3%43.5%21.3%5.6%13.1%
Q2 FY2628.0%44.2%21.1%6.4%8.6%
Q3 FY2628.0%43.5%21.5%6.7%2.5%
Q4 FY2628.0%42.6%22.8%6.4%2.5%
Q1 FY2728.0%41.5%23.7%6.5%2.5%
Q2 FY2728.0%43.2%22.1%6.5%2.9%

* Pledged = share of the promoters' own holding reported as pledged. In older filings this can include shares “otherwise encumbered”; the governance flags say when.

18What it does with profit

18What it does with profit

What does Apollo Hospitals do with its profit?

Dividend per share is interim plus final; FY26 had ₹10 interim (paid 27 Feb 2026) and ₹10 final (record date 14 Aug 2026). Payout = dividend per share ÷ earnings per share (Cityfort calculation). Apollo paid ₹293 crore of dividends in FY26. The share count, 143,784,657, did not change from Dec 2023 to Sep 2026, and there was no buyback.

Dividend per share

₹20.00FY26

Dividend paid for each share, by financial year.

₹ per share

See the numbers
Dividend per share (₹ per share)
YearDividend per shareShare of profit paid out
FY24₹16.0025.6%
FY25₹19.0018.9%
FY26₹20.0014.8%

No buybacks or fund raises in the period covered.

19Governance signals

19Governance signals

What do Apollo Hospitals' governance filings show?

Auditor
Deloitte Haskins & Sells LLP
Auditor changes
None in the period covered
Audit qualifications
None reported
Related-party dealings
The research for this page did not collect related-party amounts. Keimed, a drug wholesaler that merges into Apollo Healthtech under the scheme, is a related party of Apollo. Under a 30 Jun 2025 agreement, Rasmeli, an Apollo HealthCo investor linked to Advent, will share an agreed part of its gains with Shobana Kamineni, Apollo HealthCo's promoter, and designated employees.
Credit rating
ICRA [ICRA]AAA (long term), [ICRA]A1+ (short term) (outlook Stable), 18 May 2026

A credit rating describes the company's ability to repay debt. It is not a rating of the share.

Flags to know about

  • pledge · 30 Sep 2026

    Promoter shares pledged

    2.91% of the promoter group's shares were pledged as loan collateral on 30 Sep 2026, up from 2.49% on 30 Jun 2026.

  • auditor

    Auditor's final term ends in 2027

    Deloitte Haskins & Sells LLP is in its second and final five-year term, which ends at the 46th annual meeting in 2027. A new auditor must then be appointed.

  • regulatory · 10 Apr 2026

    Karnataka land order against a subsidiary

    On 13 Feb 2026 Karnataka's Revenue Department cancelled a land grant to subsidiary Imperial Hospitals & Research Centre, alleging the land had been alienated through a share purchase by its holding company. The High Court of Karnataka granted an interim stay against the order on 10 Apr 2026. The auditor drew attention to the matter without modifying its Q2 FY27 review conclusion.

  • other

    Promoter family runs the company

    Members of the promoter family hold the posts of Executive Chairman, Executive Vice Chairperson, Managing Director and Joint Managing Director. The board lists 10 directors, including Shobana Kamineni as a promoter director; 5 are independent.

  • related party · 30 Jun 2025

    Advent gain-sharing arrangement

    Rasmeli, an Apollo HealthCo shareholder linked to Advent, agreed on 30 Jun 2025 to share an agreed part of its gains with Shobana Kamineni, Apollo HealthCo's promoter, and designated employees, to reward management.

  • disclosure

    Hospital measures changed

    Apollo stopped reporting revenue per occupied bed after FY25 (₹60,588 a day) and now reports average revenue per inpatient (₹186,880 in Q2 FY27). The two do not compare. Its deck's hospital revenue also differs from the segment note.

  • disclosure

    Comparisons break twice

    Cradle and Fertility were re-presented as discontinued from Q2 FY27, with only some earlier periods restated. The pharmacy demerger, once effective, will break the history again; no restated series without it has been published.

20What the market paid

20What the market paid · price as of 11 Nov 2026

What did the market pay for Apollo Hospitals on 11 Nov 2026?

Price as of 11 Nov 2026 (shown for education; prices change daily).

Price as of 11 Nov 2026: ₹8,604.00, the NSE closing price. Market value = price × 143,784,657 shares = ₹123,712 crore. P/E (price ÷ earnings per share) = ₹8,604 ÷ FY26 earnings per share of ₹135.04 = 63.7. P/B (market value ÷ equity of Apollo's shareholders on 30 Sep 2026, ₹10,604 crore) = 11.7. All are Cityfort calculations from NSE prices and Apollo's filings.

Share price
₹8,604.00
Market value (market cap)
₹123,712 cr
P/E
63.7×
P/B
11.7×

Source: NSE historical price data, APOLLOHOSP (EQ series), 2-11 Nov 2026; Shareholding pattern, quarter ended Sep 2026 (XBRL); Q4 FY26 and FY26 audited consolidated results, XBRL (integrated filing) and 1 more

21How it got here

21How it got here

How did Apollo Hospitals get here?

  1. 1983

    Milestone

    Founded

    Dr Prathap C. Reddy founded Apollo Hospitals in 1983; the annual report calls it India's first corporate hospital.

  2. 2017

    Crisis

    Price caps on stents and implants

    Government caps on cardiac stent and knee implant prices hurt revenue and profit in FY17 and FY18, CRISIL notes.

  3. 2022

    Business-model change

    Apollo HealthCo formed

    From 16 Mar 2022 pharmacy distribution and Apollo 24/7 sit together in the subsidiary Apollo HealthCo.

  4. 2025

    Business-model change

    Plan to split off pharmacy and digital

    On 30 Jun 2025 the board approved a scheme to move them into Apollo Healthtech, merge in Keimed and list it.

  5. 2025

    Milestone

    Promoter group sells 1.3%

    On 22 Aug 2025 the promoter group sold 1,897,239 shares by block deal to reduce promoter-group debt.

  6. 2026

    Milestone

    Full control of AHLL

    Apollo bought IFC's 30.58% of its clinics arm AHLL for ₹1,254 crore (completed 23 Mar 2026); AHLL became wholly owned on 10 Apr 2026.

  7. 2026

    Milestone

    Shareholders approve the scheme

    A tribunal-convened shareholder meeting approved the Apollo Healthtech scheme on 24 Jun 2026.

  8. 2026

    Business-model change

    Cradle and Fertility sold

    On 12 Oct 2026 the maternity and fertility units went to Kids Clinic India (Cloudnine) for ₹1,550 crore: ₹764 crore of cash and debt transfer, and a 9.9% stake valued at ₹786 crore.

Used in a free classroom lesson: When promoters pledge shares.

22Sources and changes

Where every number on this page comes from

Sources (45 documents)
  1. S1Annual Report FY26 (updated version, re-filed 28 Aug 2026) · Apollo Hospitals Enterprise Ltd (filed with NSE) · Tier 1: company or exchange filing · 28 Aug 2026
  2. S4Q2 FY27 results: outcome of board meeting, unaudited results, notes, change in senior management (4 Nov 2026) · Apollo Hospitals Enterprise Ltd (filed with NSE) · Tier 1: company or exchange filing · 4 Nov 2026
  3. S5Q2 FY27 consolidated results, XBRL (integrated filing) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 4 Nov 2026
  4. S6Q1 FY27 consolidated results, XBRL (integrated filing) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 12 Aug 2026
  5. S7Q4 FY26 and FY26 audited consolidated results, XBRL (integrated filing) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 20 May 2026
  6. S8Q3 FY26 consolidated results, XBRL (integrated filing) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 10 Feb 2026
  7. S9Q2 FY26 consolidated results, XBRL (integrated filing) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 6 Nov 2025
  8. S10Q1 FY26 consolidated results, XBRL (integrated filing) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 12 Aug 2025
  9. S11Q4 FY25 and FY25 audited consolidated results, XBRL (integrated filing) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 30 May 2025
  10. S12Q3 FY25 consolidated results, XBRL · NSE (company XBRL filing) · Tier 1: company or exchange filing · 10 Feb 2025
  11. S13Q2 FY25 consolidated results, XBRL · NSE (company XBRL filing) · Tier 1: company or exchange filing · 6 Nov 2024
  12. S14Q1 FY25 consolidated results, XBRL · NSE (company XBRL filing) · Tier 1: company or exchange filing · 14 Aug 2024
  13. S15Q4 FY24 and FY24 audited consolidated results, XBRL · NSE (company XBRL filing) · Tier 1: company or exchange filing · 31 May 2024
  14. S16Q4 FY23 and FY23 audited consolidated results, XBRL · NSE (company XBRL filing) · Tier 1: company or exchange filing · 31 May 2023
  15. S17Q4 FY22 and FY22 audited consolidated results, XBRL · NSE (company XBRL filing) · Tier 1: company or exchange filing · 26 May 2022
  16. S18Earnings update Q2 FY27 (investor presentation) · Apollo Hospitals Enterprise Ltd (filed with NSE) · Tier 1: company or exchange filing · 4 Nov 2026
  17. S19Earnings update Q1 FY27 (investor presentation) · Apollo Hospitals Enterprise Ltd (filed with NSE) · Tier 1: company or exchange filing · 12 Aug 2026
  18. S22Transcript of Q2 FY27 earnings call (5 Nov 2026) · Apollo Hospitals Enterprise Ltd (company site; link filed with NSE 11 Nov 2026) · Tier 1: company or exchange filing · 11 Nov 2026
  19. S24Transcript of Q4 FY26 earnings call (21 May 2026) · Apollo Hospitals Enterprise Ltd (company site; link filed with NSE 25 May 2026) · Tier 1: company or exchange filing · 25 May 2026
  20. S25Transcript of Q3 FY26 earnings call (11 Feb 2026) · Apollo Hospitals Enterprise Ltd (company CDN; link filed with NSE 14 Feb 2026) · Tier 1: company or exchange filing · 14 Feb 2026
  21. S26Shareholding pattern, quarter ended Sep 2026 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 7 Oct 2026
  22. S27Shareholding pattern, quarter ended Jun 2026 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 3 Jul 2026
  23. S28Shareholding pattern, quarter ended Mar 2026 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 9 Apr 2026
  24. S29Shareholding pattern, quarter ended Dec 2025 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 6 Jan 2026
  25. S30Shareholding pattern, quarter ended Sep 2025 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 8 Oct 2025
  26. S31Shareholding pattern, quarter ended Jun 2025 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 8 Jul 2025
  27. S32Shareholding pattern, quarter ended Mar 2025 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 10 Apr 2025
  28. S33Shareholding pattern, quarter ended Dec 2024 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 16 Jan 2025
  29. S34Shareholding pattern, quarter ended Sep 2024 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 9 Oct 2024
  30. S35Shareholding pattern, quarter ended Jun 2024 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 9 Jul 2024
  31. S36Shareholding pattern, quarter ended Mar 2024 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 8 Apr 2024
  32. S37Shareholding pattern, quarter ended Dec 2023 (XBRL) · NSE (company XBRL filing) · Tier 1: company or exchange filing · 5 Jan 2024
  33. S38Crisil Ratings rating rationale: AHEL bank facilities and NCDs, CRISIL AA+/Positive and CRISIL A1+ (filed with NSE 27 Jan 2026) · Crisil Ratings Ltd (letter filed by the company with NSE) · Tier 2: rating agency or regulator · 27 Jan 2026
  34. S39ICRA rating letter: [ICRA]AAA (Stable) and [ICRA]A1+ assigned on Rs 3,000 crore of facilities (letter dated 18 May 2026) · ICRA Ltd (letter filed by the company with NSE) · Tier 2: rating agency or regulator · 19 May 2026
  35. S40Board approves composite scheme: demerger of omni-channel pharmacy and digital health into Apollo Healthtech Ltd, amalgamation of Apollo HealthCo and Keimed, listing (30 Jun 2025) · Apollo Hospitals Enterprise Ltd (filed with NSE) · Tier 1: company or exchange filing · 30 Jun 2025
  36. S41Promoter group sells 1,897,239 shares (1.3%) by block deal; pledge update (22 Aug 2025) · Apollo Hospitals Enterprise Ltd (filed with NSE) · Tier 1: company or exchange filing · 22 Aug 2025
  37. S42Board outcome: purchase of 30.58% of AHLL from IFC for Rs 12,540.68 million; Gurugram oncology and proton centre (12 Sep 2025) · Apollo Hospitals Enterprise Ltd (filed with NSE) · Tier 1: company or exchange filing · 12 Sep 2025
  38. S44Completion of AHLL stake purchase from IFC and IFC EAF; holding 99.42% (23 Mar 2026) · Apollo Hospitals Enterprise Ltd (filed with NSE) · Tier 1: company or exchange filing · 23 Mar 2026
  39. S45AHLL becomes a 100% subsidiary after purchase from individual shareholders (10 Apr 2026) · Apollo Hospitals Enterprise Ltd (filed with NSE) · Tier 1: company or exchange filing · 10 Apr 2026
  40. S47Press release: Apollo Cradle and Fertility combine with Cloudnine, valued at Rs 1,550 crore (cash plus 9.9% stake) (20 May 2026) · Apollo Hospitals Enterprise Ltd (filed with NSE) · Tier 1: company or exchange filing · 20 May 2026
  41. S48Resignation of Dinesh Madhavan, President - Group Oncology and International (30 May 2026) · Apollo Hospitals Enterprise Ltd (filed with NSE) · Tier 1: company or exchange filing · 30 May 2026
  42. S49Proceedings of the NCLT-convened meeting of equity shareholders on the composite scheme (24 Jun 2026) · Apollo Hospitals Enterprise Ltd (filed with NSE) · Tier 1: company or exchange filing · 24 Jun 2026
  43. S50NSE historical price data, APOLLOHOSP (EQ series), 2-11 Nov 2026 · National Stock Exchange of India · Tier 1: company or exchange filing · 11 Nov 2026
  44. S51Business Responsibility and Sustainability Report FY26 (section of Annual Report FY26) · Apollo Hospitals Enterprise Ltd (filed with NSE) · Tier 1: company or exchange filing · 28 Aug 2026
  45. S53NSE corporate announcements list for APOLLOHOSP (dividend and record-date entries, Feb 2023 - Nov 2026) · National Stock Exchange of India · Tier 1: company or exchange filing · 11 Nov 2026
Changes to this page (v1 · 11 Nov 2026)
  1. v1 · 11 Nov 2026First version. (first version)

Numbers come only from tier 1 and tier 2 sources. Read how we research.

Disclaimer

For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a SEBI-registered investment adviser.

Cityfort, its owners and contributors may or may not hold securities of companies covered. Content is not an offer or solicitation to buy or sell any security.

Read the full disclaimer

Cityfort publishes educational content that explains how listed companies work. Cityfort is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst and does not provide investment advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security.

All information is taken from publicly available sources, mainly company filings on BSE and NSE, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.

Statements by company management are reported as statements, with their date and source; they are not our forecasts.